L Number	Hits	Search Text	DB	Time stamp
1	30	"5133908"	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/03 13:26
7	35277	casein	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/03 13:26
13	401	casein and nanoparticle$2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/03 13:26
19	35	casein and nanoparticle$2.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/03 14:27
25	10676	casein same gelatin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/03 14:27
31	591	casein same gelatin.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/03 14:27
37	15	(casein same gelatin.clm.) and nanoparticle$2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/03 14:27
-	489	Heger.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 09:47
-	20	Heger.in. and Auweter.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 09:49
-	3	heger.in. and nanoparticle$2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 09:58
-	4	Auweter.in. and nanoparticle$2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 09:59
-	403	Breitenbach.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 10:00
-	1	Breitenbach.in. and nanoparticle$2	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 10:00

-	1200	bohn.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 10:21
-	2	5133908.pn.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 10:21
-	1117	nanoparticle$2 and polymer$2.clm.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 10:21
-	345	nanoparticle$2 and polymer$2.clm. and gelatin	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 11:02
-	78	Rollat.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 11:02
-	7	Rollat.in. and polyurethane	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/04/02 11:02

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600rkb

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 40	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 41	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 42	Feb 13	CANCERLIT is no longer being updated
NEWS 43	Feb 24	METADEX enhancements
NEWS 44	Feb 24	PCTGEN now available on STN

```
 NEWS 45   Feb 24  TEMA now available on STN
 NEWS 46   Feb 26  NTIS now allows simultaneous left and right truncation
 NEWS 47   Feb 26  PCTFULL now contains images
 NEWS 48   Mar 04  SDI PACKAGE for monthly delivery of multifile SDI results
 NEWS 49   Mar 19  APOLLIT offering free connect time in April 2003
 NEWS 50   Mar 20  EVENTLINE will be removed from STN
 NEWS 51   Mar 24  PATDPAFULL now available on STN
 NEWS 52   Mar 24  Additional information for trade-named substances without
                   structures available in REGISTRY
 NEWS 53   Mar 24  Indexing from 1957 to 1966 added to records in CA/CAPLUS

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 15:10:16 ON 03 APR 2003

=> file caplus uspatfull biosis europatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'CAPLUS' ENTERED AT 15:10:53 ON 03 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:10:53 ON 03 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:10:53 ON 03 APR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EUROPATFULL' ENTERED AT 15:10:53 ON 03 APR 2003
COPYRIGHT (c) 2003 WILA Verlag Muenchen (WILA)

=>
=> s nanoparticle? and (gelatin or casein)
L1         1648 NANOPARTICLE? AND (GELATIN OR CASEIN)

=> s l1 and matrix?
L2          981 L1 AND MATRIX?

=> s l2 and (pharmaceutical or drug? or active agent or peptide?)
```

```
L3          953 L2 AND (PHARMACEUTICAL OR DRUG? OR ACTIVE AGENT OR PEPTIDE?)

=> s l3 and gelatin
L4          896 L3 AND GELATIN

=> s l4 and hydrosol
L5           12 L4 AND HYDROSOL

=> d l5 1-12 abs bib
```

L5 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS

AB Nanoparticulate prepns. of **pharmaceutical** and cosmetic active substances with a core-shell structure are described, wherein the active substance is present in the core as x-ray amorphous particles dispersed in a polymer **matrix**, and the shell consists of a stabilizing sheathing **matrix** of a swellable polymer. The polymer **matrix** in the core prevents crystn. and pptn. of the active substance in the presence of solvent. The polymeric shell maintains the core-shell particles in a colloidal state, preventing aggregation or flocculation. Thus, cyclosporin A 3 was suspended in a soln. of ascorbyl palmitate 0.6 and Kollicoat MAE 0.6 in iso-PrOH 36 g. This suspension was then mixed with 120 g H2O at 200.degree. for 0.3 s, followed by mixing with a soln. of **gelatin** A 4.3 and lactose 6.5 in demineralized water 490 g (pH 9.0) at 25.degree. and 30 bar. The resulting dispersion (mean particle size 249 nm) was spray dried to a powder (cyclosporin content 20.03 wt.%) which could be redispersed in water to a **hydrosol** whose particle size remained stable at 263 nm over 1 h.

AN 2000:401632 CAPLUS

DN 133:48938

TI Nanoparticulate core-shell systems and use thereof in **pharmaceutical** and cosmetic preparations

IN Heger, Robert; Auweter, Helmut; Breitenbach, Joerg; Bohn, Heribert

PA BASF Aktiengesellschaft, Germany

SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000033820	A2	20000615	WO 1999-EP9545	19991207
	WO 2000033820	A3	20001012		
	W: CA, CN, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	DE 19856432	A1	20000615	DE 1998-19856432	19981208
	EP 1137404	A2	20011004	EP 1999-963399	19991207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002531492	T2	20020924	JP 2000-586313	19991207
PRAI	DE 1998-19856432	A	19981208		
	WO 1999-EP9545	W	19991207		

L5 ANSWER 2 OF 12 USPATFULL
AB The present invention relates to compounds that specifically block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins and that reduce expression of a member of the CD83 family of proteins in a cell as well as **pharmaceutical** compositions comprising such compounds and methods for screening and/or identifying compounds that block the binding between a member of the HuR family of proteins and a mRNA encoding a member of the CD83 family of proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:295140 USPATFULL
TI Compounds that affect CD83 expression, **pharmaceutical** compositions comprising said compounds and methods for identifying said compounds
IN Hauber, Joachim, Langensendelbach, GERMANY, FEDERAL REPUBLIC OF
Prechtel, Alexander Thorsten, Lauf an der Pegnitz, GERMANY, FEDERAL REPUBLIC OF
PI US 2002165186 A1 20021107
AI US 2001-25367 A1 20011219 (10)
PRAI GB 2000-31145 20001220
DT Utility
FS APPLICATION
LREP Leopold Presser, Esq., SCULLY, SCOTT, MURPHY & PRESSER, 400 Garden City Plaza, Garden City, NY, 11530
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 2667
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 12 USPATFULL

AB New biologically active compounds are described which inhibit the cellular formation of niacinamide mononucleotide, and essential intermediate of the NAD(P) biosynthesis in the cell. These compounds can represent the active ingredient of a **pharmaceutical** composition for the treatment of cancers, leukaemias or for immunosuppression. Furthermore, screening methods are described as a tool for detecting the above active compounds, and for examination of a given cell type for its dependency on niacinamide as a precursor for NAD synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:288098 USPATFULL

TI Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy

IN Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Eisenburger, Rolf, Kirchseeon, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Schemainda, Isabel, Munich, GERMANY, FEDERAL REPUBLIC OF
Schulz, Michael, Aschheim, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
Wosikowski, Katja, Poing, GERMANY, FEDERAL REPUBLIC OF

PA Klinge Pharma GmbH (non-U.S. corporation)

PI US 2002160968 A1 20021031
US 6506572 B2 20030114

AI US 2001-935772 A1 20010823 (9)

RLI Continuation of Ser. No. WO 2000-EP1628, filed on 28 Feb 2000, UNKNOWN

PRAI EP 1999-103814 19990226

DT Utility

FS APPLICATION

LREP FITCH EVEN TABIN AND FLANNERY, 120 SOUTH LA SALLE STREET, SUITE 1600, CHICAGO, IL, 60603-3406

CLMN Number of Claims: 25

ECL Exemplary Claim: 1

DRWN 28 Drawing Page(s)

LN.CNT 3127

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 12 USPATFULL

AB The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:239033 USPATFULL

TI Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression

IN Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Grafelfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
PA Klinge Pharma GmbH, Munich, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PI US 6451816 B1 20020917
AI US 1998-216482 19981218 (9)
RLI Continuation of Ser. No. WO 1997-EP3244, filed on 20 Jun 1997
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita
LREP Fitch, Even, Tabin, & Flannery
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 4285

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 12 USPATFULL

AB The invention relates to new pyridyl alkane acid amides according to general formula (I) as well as methods for their production, medicaments containing these compounds as well as their medical use, especially in the treatment of tumors or for immunosuppression. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:224728 USPATFULL

TI Pyridyl alkane acid amides as cytostatics and immunosuppressives

IN Biedermann, Elfi, Vaterstetten, GERMANY, FEDERAL REPUBLIC OF
Hasmann, Max, Neuried, GERMANY, FEDERAL REPUBLIC OF
Loser, Roland, Feldafing, GERMANY, FEDERAL REPUBLIC OF
Rattel, Benno, Munich, GERMANY, FEDERAL REPUBLIC OF
Reiter, Friedemann, Putzbrunn, GERMANY, FEDERAL REPUBLIC OF
Schein, Barbara, Neufahrn, GERMANY, FEDERAL REPUBLIC OF
Seibel, Klaus, Gra felfing, GERMANY, FEDERAL REPUBLIC OF
Vogt, Klaus, Munich, GERMANY, FEDERAL REPUBLIC OF
PA Klinge Pharma GmbH, Munich, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

PI US 6444823 B1 20020903
AI US 1998-216075 19981218 (9)
RLI Continuation of Ser. No. WO 1997-EP3243, filed on 20 Jun 1997
PRAI DE 1996-DE19624704 19960620
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita
LREP Fitch, Even, Tabin & Flannery
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 3772

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 12 USPATFULL

AB The invention relates to a stabilized medicament with an amount of active ingredients containing cysteine groups and NSAID compounds, wherein a stabilization of the combination, especially the active ingredients containing the cysteine group, can be conducted with a mixture of at least three anti-oxidative components. The therapeutic and prophylactic use of this medicament stabilized in this manner lies in the field of the prevention and therapy of inflammatory diseases among the fields of medical indications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:67202 USPATFULL

TI Stabilized medicament containing cysteinyl derivatives

IN Stanislaus, Fritz, Muenchen, GERMANY, FEDERAL REPUBLIC OF

PI US 2002037855 A1 20020328

AI US 2001-816769 A1 20010322 (9)

RLI Continuation of Ser. No. US 2000-403160, filed on 5 May 2000, ABANDONED A 371 of International Ser. No. WO 1997-EP1941, filed on 18 Apr 1997, UNKNOWN

DT Utility

FS APPLICATION

LREP HELLER EHRMAN WHITE & MCAULIFFE LLP, 275 MIDDLEFIELD ROAD, MENLO PARK, CA, 94025-3506

CLMN Number of Claims: 16

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1064

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 12 USPATFULL

AB The invention relates to aqueous dispersions of sparingly water-soluble or water-insoluble organic UV filter substances, which comprise at least one sparingly water-soluble or water-insoluble organic UV filter substance as colloidally disperse phase in amorphous or partially amorphous form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:160697 USPATFULL

TI Aqueous dispersion of water-insoluble organic UV filter substances

IN Heger, Robert, Heidelberg, Germany, Federal Republic of
Auweter, Helmut, Limburgerhof, Germany, Federal Republic of
Dausch, Wilma M., Limburgerhof, Germany, Federal Republic of
Zwissler, Georg Konrad, Heidelberg, Germany, Federal Republic of
Wunsch, Thomas, Speyer, Germany, Federal Republic of

PI US 2001022965 A1 20010920
US 6531117 B2 20030311

AI US 2001-771594 A1 20010130 (9)

PRAI DE 2000-10007116 20000217
DE 2000-10042444 20000829

DT Utility

FS APPLICATION

LREP Messrs. Keil & Weinkauf, 1101 Connecticut Ave., N.W., Washington, DC, 20036

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1586

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 12 USPATFULL

AB The invention relates to medicament excipient particles which are suitable for tissue-specific application of a medicament, especially to the central nervous system (CNS). The invention particles can be loaded with or be free pf the active substance. At least one detection protein is bonded to the particle surface or alternatively, the particle surface is modified in such a way that a detection protein bonds with it on contact.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:152938 USPATFULL

TI Medicament excipient particles for tissue-specific application of a medicament

IN Muller, Ranier H., Berlin, Germany, Federal Republic of
Luck, Martin, Berlin, Germany, Federal Republic of
Kreuter, Jorg, Bad Homburg, Germany, Federal Republic of

PA DSS Drug Delivery Service Gesellschaft zur Forderung der Foshung In Phamazeutischer Technologi und Biopharmazie mbH, Kronshagen, Germany, Federal Republic of (non-U.S. corporation)

PI US 6288040 B1 20010911
WO 9920256 19990429

AI US 2000-529600 20000621 (9)
WO 1998-EP6429 19981013
20000621 PCT 371 date
20000621 PCT 102(e) date

PRAI DE 1997-19745950 19971017

DT Utility

FS GRANTED

EXNAM Primary Examiner: Davenport, Avis M.

LREP Melcher, Jeffrey S.Manelli Denison & Selter, PLLC

CLMN Number of Claims: 55

ECL Exemplary Claim: 1

DRWN 4 Drawing Figure(s); 4 Drawing Page(s)

LN.CNT 999

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 12 EUROPATFULL COPYRIGHT 2003 WILA

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

AN 1031564 EUROPATFULL ED 20000910 EW 200035 FS OS
TIEN Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy.
TIDE Hemmer der Nicotinamidmononononukleotide-Bildung und deren Verwendung zur Krebstherapie.
TIFR Inhibiteurs de la formation du nicotinamide mononucleotide et leur utilisation dans le traitement du cancer.
IN Biedermann, Elfi, Zugspitzstrasse 93, 85591 Vaterstetten, DE;
Eisenburger, Rolf Dr., Rathausstrasse 4, 85614 Kirchseeon, DE;
Hasmann, Max Dr., Lerchenweg 9, 82061 Neuried, DE;
Loeser, Roland Dr., Fichtenweg 2, 82340 Feldafing, DE;
Rattel, Benno Dr., Eichelhaeherstrasse 3, 81249 Muenchen, DE;
Reiter, Friedemann Dr., Zugspitzstrasse 36, 85640 Putzbrunn, DE;
Schein, Barbara, Sudetenweg 3, 85375 Neufahrn, DE;
Schemainda, Isabel, Hoerwarthstrasse 47, 80804 Muenchen, DE;
Schulz, Michael Dr., Sonnenstrasse 6, 85609 Aschheim, DE;
Seibel, Klaus Prof. Dr., Haberlstrasse 9, 82166 Graefelfing, DE;
Vogt, Klaus Dr., St.-Cajetan-Strasse 32, 81669 Muenchen, DE;
Wosikowski, Katja Dr., Seerosenstrasse 3, 85586 Poing, DE
PA Klinge Pharma GmbH, Berg-am-Laim-Strasse 129, D-81673 Muenchen, DE
PAN 283200
AG HOFFMANN - EITLE, Patent- und Rechtsanwaelte Arabellastrasse 4, 81925 Muenchen, DE
AGN 101511
OS BEPA2000067 EP 1031564 A1 0024
SO Wila-EPZ-2000-H35-T1a
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R CY; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE; R AL; R LT; R LV; R MK; R RO; R SI
PIT EPA1 EUROPAEISCHE PATENTANMELDUNG
PI EP 1031564 A1 20000830
OD 20000830
AI EP 1999-103814 19990226

L5 ANSWER 10 OF 12 EUROPATFULL COPYRIGHT 2003 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 934309 EUROPATFULL ED 20020917 EW 200237 FS PS
TIEN NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES.
TIDE PYRIDYLALKAN-SAeUREAMIDE ALS CYTOSTATIKA UND IMMUNOSUPRESSIVE ARZNEIMITTEL.
TIFR NOUVEAUX AMIDES A ACIDES PYRIDYL-ALCANE UTILISES COMME CYTOSTATIQUES ET IMMUNOSUPPRESSEURS.
IN BIEDERMANN, Elfi, Zugspitzstrasse 93, D-85591 Vaterstetten, DE;
HASMANN, Max, Lerchenweg 9, D-82061 Neuried, DE;
LOeSER, Roland, Fichtenweg 2, D-82340 Feldafing, DE;
RATTEL, Benno, Eichelhaeherstrasse 3, D-81249 Munich, DE;
REITER, Friedemann, Zugspitzstrasse 36, D-85640 Putzbrunn, DE;
SCHEIN, Barbara, Sudetenweg 4, D-85375 Neufahrn, DE;
SEIBEL, Klaus, Haberlstrasse 9, D-82166 Graefelfing, DE;
VOGT, Klaus, Balanstrasse 63, D-81541 Munich, DE
PA Fujisawa Deutschland GmbH, Berg-am-Laim-Strasse 129, 81673 Muenchen, DE
PAN 283202
AG HOFFMANN - EITLE, Patent- und Rechtsanwaelte Arabellastrasse 4, 81925 Muenchen, DE
AGN 101511
OS BEPB2002065 EP 0934309 B1 0123
SO Wila-EPS-2002-H37-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PI EP 934309 B1 20020911
OD 19990811
AI EP 1997-929240 19970620
PRAI DE 1996-19624704 19960620
RLI WO 97-EP3243 970620 INTAKZ
WO 9748695 971224 INTPNR
REP EP 330026 A EP 343307 A
WO 91-15484 A WO 91-15485 A

L5 ANSWER 11 OF 12 EUROPATFULL COPYRIGHT 2003 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 923570 EUROPATFULL ED 20021007 EW 200239 FS PS
TIEN PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES.
TIDE PYRIDYLALKEN- UND PYRIDYLALKIN-SAeUREAMIDE ALS CYTOSTATIKA UND IMMUNOSUPPRESSIVE ARZNEIMITTEL.
TIFR AMIDES PYRIDYL-ALCENE ET PYRIDYL-ALCYNE ACIDES UTILISES COMME CYTOSTATIQUES ET IMMUNOSUPPRESSEURS.
IN BIEDERMANN, Elfi, Zugspitzstrasse 93, D-85591 Vaterstetten, DE;
HASMANN, Max, Lerchenweg 9, D-82061 Neuried, DE;
LOeSER, Roland, Fichtenweg 2, D-82340 Feldafing, DE;
RATTEL, Benno, Eichelhaeherstrasse 3, D-81249 Munich, DE;
REITER, Friedemann, Zugspitzstrasse 36, D-85640 Putzbrunn, DE;
SCHEIN, Barbara, Sudetenweg 4, D-85375 Neufahrn, DE;
SEIBEL, Klaus, Haberlstrasse 9, D-82166 Graefelfing, DE;
VOGT, Klaus, Balanstrasse 63, D-81541 Munich, DE
PA Fujisawa Deutschland GmbH, Berg-am-Laim-Strasse 129, 81673 Muenchen, DE
PAN 283202
AG HOFFMANN - EITLE, Patent- und Rechtsanwaelte Arabellastrasse 4, 81925 Muenchen, DE
AGN 101511
OS BEPB2002069 EP 0923570 B1 0124
SO Wila-EPS-2002-H39-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PI EP 923570 B1 20020925
OD 19990623
AI EP 1997-928261 19970620
PRAI DE 1996-19624659 19960620
RLI WO 97-EP3245 970620 INTAKZ
WO 9748696 971224 INTPNR
REP EP 330026 A EP 343307 A

L5 ANSWER 12 OF 12 EUROPATFULL COPYRIGHT 2003 WILA

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

AN 912176 EUROPATFULL ED 20021007 EW 200239 FS PS
TIEN USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION.
TIDE VERWENDUNG VON PYRIDYL-ALKAN-,PYRIDIYL ALKAN- UND/ODER PYRIDYL-SAeUREN AMIDEN ZUR BEHANDLUNG VON TUMOREN ODER FUeR IMMUNSUPPRESSION.
TIFR UTILISATION D'AMIDES PYRIDYL-ALCANE, PYRIDYL-ALCENE ET/OU PYRIDYL-ALCYNE ACIDES DANS LE TRAITEMENT DES TUMEURS ET POUR L'IMMUNOSUPPRESSION.
IN BIEDERMANN, Elfi, Zugspitzstrasse 93, D-85591 Vaterstetten, DE;
HASMANN, Max, Lerchenweg 9, D-82061 Neuried, DE;
LOeSER, Roland, Fichtenweg 2, D-82340 Feldafing, DE;
RATTEL, Benno, Eichelhaeherstrasse 3, D-81249 Munich, DE;
REITER, Friedemann, Zugspitzstrasse 36, D-85640 Putzbrunn, DE;
SCHEIN, Barbara, Sudetenweg 4, D-85375 Neufahrn, DE;
SEIBEL, Klaus, Haberlstrasse 9, D-82166 Graefelfing, DE;
VOGT, Klaus, Balanstrasse 63, D-81541 Munich, DE
PA Fujisawa Deutschland GmbH, Berg-am-Laim-Strasse 129, 81673 Muenchen, DE
PAN 283202
AG HOFFMANN - EITLE, Patent- und Rechtsanwaelte Arabellastrasse 4, 81925 Muenchen, DE
AGN 101511
OS BEPB2002068 EP 0912176 B1 0152
SO Wila-EPS-2002-H39-T1
DT Patent
LA Anmeldung in Englisch; Veroeffentlichung in Englisch
DS R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PIT EPB1 EUROPAEISCHE PATENTSCHRIFT (Internationale Anmeldung)
PI EP 912176 B1 20020925
OD 19990506
AI EP 1997-928260 19970620
PRAI DE 1996-19624668 19960620
RLI WO 97-EP3244 970620 INTAKZ
WO 9748397 971224 INTPNR
REP EP 210782 A EP 330026 A
EP 343307 A WO 91-15484 A
WO 91-15485 A

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	71.48	71.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-0.65

STN INTERNATIONAL LOGOFF AT 15:29:15 ON 03 APR 2003